Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Dec 10;52(1):e7784.
doi: 10.1590/1414-431X20187784.

CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis

A Nonino  1   2 , J M Nascimento  2   3 , C C Mascarenhas  1 , J F Mazzeu  3 , R W Pereira  1 , R H Jacomo  4
Affiliations
Comparative Study

CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis

A Nonino et al. Braz J Med Biol Res. .

Abstract

Myelofibrosis (MF) is characterized by increased circulating hematopoietic progenitor cells (HPCs), abnormal cytokine levels, and the survival advantage of neoplastic progenitors over their normal counterparts, which leads to progressive disappearance of polyclonal hematopoiesis. CD47 is a surface glycoprotein with many functions, such as acting as a phagocytosis inhibitor of the expressing cell, that is increased in normal hematopoietic stem and progenitor cells mobilized into the blood and several human cancer-initiating cells, such as in acute myeloid leukemia. We compared CD47 expression in hematopoietic stem and progenitor cells of patients with MF and controls and found it to be decreased in progenitors of MF. Exposure of control HPCs to the cytokines transforming growth factor β and stromal-derived factor 1, which are important regulators of hematopoietic stem cell cycling and are overexpressed in patients with MF, did not modulate CD47 expression.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Gating Strategy. LCP: lineage committed progenitors; PPC: pluripotential progenitor cells; HSC: hematopoietic stem cells.
Figure 2
Figure 2. CD47 expression in control vs myelofibrosis (MF) CD34-positive (pos) cells. A, Histogram of representative experiments; B, Comparison of average mean fluorescence intensity (MFI). Data are reported as mean±SD; Welch-corrected Student's t-test. PMF: primary myelofibrosis.
Figure 3
Figure 3. CD47 expression in different cell compartments of control vs myelofibrosis (MF) cells. A, Histograms of representative experiments; B, Comparison of average mean fluorescence intensity (MFI) (Welch-corrected Student's t-test). Data are reported as mean±SD. HSC: hematopoietic stem cells; PPC: pluripotential progenitor cells; LCP: lineage committed progenitors; DC: differentiated cells.
Figure 4
Figure 4. Comparison of CD47 expression among different CD34-positive cell compartments (ANOVA with Bonferroni post-test). Data are reported as mean±SD. A, Patients with myelofibrosis; B, Controls; MFI: Mean fluorescence intensity; HSC: hematopoietic stem cells; PPC: pluripotential progenitor cells; LCP: lineage committed progenitors; ns: non-significant.
Figure 5
Figure 5. CD47 expression after exposure to SDF-1 and TGF-ß. A, Comparison in CD34 positive cells and B, Hematopoietic stem cells (Welch-corrected Student's t-test). Data are reported as mean±SD. MFI: mean fluorescence intensity.
See this image and copyright information in PMC

References

    1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265. doi: 10.1056/NEJM200004273421706. - DOI - PubMed
    1. Orvain C, Luque Paz D, Dobo I, Cottin L, Le Calvez G, Chauveau A, et al. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol. 2016;95:1819–1823. doi: 10.1007/s00277-016-2784-x. - DOI - PubMed
    1. Rameshwar P, Chang VT, Thacker UF, Gascón P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis--pathophysiological implications. Am J Hematol. 1998;59:133–142. doi: 10.1002/(SICI)1096-8652(199810)59:2<133::AID-AJH6>3.0.CO;2-Z. - DOI - PubMed
    1. Le Bousse-Kerdilàs MC, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88:4534–4546. - PubMed
    1. Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1low mouse model of the disease. Exp Hematol. 2008;36:158–171. doi: 10.1016/j.exphem.2007.10.001. - DOI - PMC - PubMed

Publication types